About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX) is a Healthcare company in the Biological Products, (No Diagnostic Substances) industry with a market capitalisation of $2.2B.
- Sector
- Healthcare
- Industry
- Biological Products, (No Diagnostic Substances)
- Market cap
- $2.2B
- EPS (TTM)
- $-1.44
- Revenue (TTM)
- $74.7M
- Free cash flow
- -$378.3M
- Profit margin
- -863.4%
- Shares outstanding
- 535.3M
Financial health: Weak2.9/10
2 strengths, 5 concerns. Weakest points: return on equity, gross margin, net margin and 2 more.
- Current ratio: 5.50 (Strong, benchmark > 1.5) — Short-term assets cover 5.50x short-term liabilities, against Graham's 1.5x floor. It has been broadly flat over the last 4 years.
- Return on equity: -57.0% (Concern, benchmark > 15%) — Earns -57.0% on shareholder equity, well short of the > 15% mark.
- Gross margin: 1.8% (Concern, benchmark > 40%) — Keeps 1.8% of revenue after the direct cost of sales, well short of the > 40% mark.
- Net margin: -863.4% (Concern, benchmark > 10%) — Turns -863.4% of revenue into profit, well short of the > 10% mark.
- Free cash flow: -$378.3M (Concern, benchmark positive) — Burned $378.3M of cash after capital spending, so operations did not fund themselves. It has deteriorated over the last 4 years.
- Revenue growth: 26.9% (Strong, benchmark > 10%) — Revenue changed 26.9% year on year, comfortably past the > 10% mark.
- Earnings growth: -39.1% (Concern, benchmark > 10%) — Earnings changed -39.1% year on year, well short of the > 10% mark.